The Conversation (0)
Alder BioPharmaceuticals Presents New 12-Month Data of Eptinezumab in PROMISE 1 Phase 3 Trial Showing Long-Term Reduction in Episodic Migraine
Apr. 24, 2018 09:15AM PST
Biotech InvestingAlder BioPharmaceuticals (NASDAQ:ALDR) a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced new twelve-month data from its PROMISE 1 Phase 3 clinical trial in episodic migraine patients. As quoted in the press release: The data demonstrated that patients experienced even further reductions in migraine following the third and …
Alder BioPharmaceuticals (NASDAQ:ALDR) a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced new twelve-month data from its PROMISE 1 Phase 3 clinical trial in episodic migraine patients.
As quoted in the press release:
The data demonstrated that patients experienced even further reductions in migraine following the third and fourth quarterly infusions at both dose levels (100mg and 300mg) of eptinezumab, Alder’s lead investigational product candidate for migraine prevention targeting calcitonin gene-related peptide (CGRP). Detailed results will be presented today at the 70th Annual American Academy of Neurology Meeting in Los Angeles.
“These results show eptinezumab’s potential to further reduce migraine risk after 12 months and reinforces the demonstrated clinical profile for migraine prevention from our earlier PROMISE 1, 6-month data,” said Roger K. Cady, M.D., Alder Vice President of Neurology. “The strength of the data supports our belief that eptinezumab, if approved, has the potential to be an important treatment option for the millions of patients living with the debilitating effects of migraine.”